Browsing by Subject "Neglected tropical disease"
Results Per Page
Sort Options
Item Open Access A One-Health Approach to Understanding the Epidemiology of Cutaneous Leishmaniasis(2021) Lana, Justin ThomasAmerican cutaneous leishmaniasis (CL) is a severely understudied and neglected“disease of poverty” widespread throughout Peru. Transmission dynamics of CL are complex, requiring sandfly vectors and mammalian reservoir hosts to maintain the pathogen in a local environment whereby incidental hosts (people) can become infected. We employed a One-Health approach to understand CL transmission in rapidly changing region of northern Peru. We describe the characteristics of 529 CL positive patients from four participating clinics. Using conditional logistic regression, we assessed risk factors of CL for residents of small urban areas through a matched case-control study with 63 patients who had visited one of the same clinics for CL (cases) or other medical reasons (controls). We later enrolled 343 households as part of a community based study occurring in 15 urban and rural areas of Soritor. We found 256 positive humans (n= 914) as tested via the Montenegro Skin Test; we found 11 positive dogs (n = 236) via an immunofluorescence antibody test. Our results suggest that most- if not all- of CL transmission is occurring in rural areas and that urban women and urban children engage in many high risk activities typically attributed to men. We find evidence that prevalence of past infection is highest among rural residents and men. We believe dogs are unlikely Leishmania reservoirs in either rural or urban settings. It remains unknown if the high number of MST positive children in rural areas is a result of peridomestic or intradomestic transmission.
Item Open Access Adapting a Novel Lateral Flow Immunoassay to Rapidly Detect Burkholderia pseudomallei in Sarawak, Malaysia(2019) Choi, JessicaBackground
Melioidosis is a neglected tropical disease that is highly prevalent in Southeast Asia. Misdiagnoses are common as the presenting symptoms are similar to other diseases including upper respiratory infections. When not treated with antibiotics, the disease can lead to severe morbidity or death. Current diagnostics in low- and middle-income countries are often not sensitive nor rapid. Point-of-care rapid diagnostic tests (POC-RDTs) are a potential solution. Few studies have compared the accuracy of POC-RDTs and molecular assays against blood culture. The goal of this study was to conduct such comparisons in detecting Burkholderia pseudomallei infections among infection-suspected patients in Kapit, Sarawak, Malaysia.
Methods
We used an informed consent process as approved by two institutional review boards. In this cross-sectional study, we engaged patients meeting a melioidosis-like case definition that included classical symptoms such as prolonged fever with joint pain and/or abscess. We studied the patients routinely collected clinical specimens with a POC-RDT (Active Melioidosis DetectTM) and a molecular assay compared with the B. pseudomallei bacterial culture for isolation of the bacterial organism.
Results
One hundred patients aged 6 months - 79 years from Kapit Hospital were enrolled in the study from June 12, 2018 to January 8, 2019. Of the 100 sera, 97 urine, and 16 bodily fluid samples (total n= 213) tested with the RDT, 23 samples gave positive results (7 sera, 15 urine, and 1 bodily fluids). Compared to the molecular assay, the POC-RDT had a sensitivity of 40% (95% CI, 5%- 85%), specificity of 94% (95% CI, 87% - 98%), and an accuracy of 90% (95 CI, 82% - 95%) for sera; and a sensitivity of 80% (95% CI, 28%- 99%),a specificity of 65% (95% CI, 55% - 75%), and an accuracy of 87% (95 CI, 77% - 94%) for urine; and a sensitivity of 80% (95% CI, 28%- 99%), a specificity of 65% (95% CI, 55% - 75%), and an accuracy of 81% (95 CI, 54% - 96%) for other bodily fluids. Additionally, when compared to the bacterial culture results, the POC-RDT showed a sensitivity of 38% (95% CI, 9%- 76%), specificity of 95% (95% CI, 88% - 99%), and an accuracy of 90% (95 CI, 82% - 95%) for sera; a sensitivity of 88% (95% CI, 47%- 100%), a specificity of 88% (95% CI, 77% - 95%), and an accuracy of 94% (95 CI, 84% - 98%) for urine; and a sensitivity of 25% (95% CI, 1%- 81%), a specificity of 100% (95% CI, 74% - 100%), and an accuracy of 81% (95 CI, 54% - 96%) for other bodily fluids.
Conclusion
While study enrollment will continue, data from the first 100 participants, suggests the POC-RDT had poor sensitivity, good accuracy, and high specificity in detecting B. pseudomallei infection. Thus far, the POC-RDT assay seems to work better on urine specimens. Due to low sensitivity, the study data do not support recommending POC-RDT strips as a single diagnostic method. However, as the POC-RDT had high specificity when the test is positive it seems appropriate for clinicians to assume the patient is infected and to prescribe specific antimicrobial therapy. While more participant data are needed, it seems likely that the POC-RDT could be useful in helping physicians to begin treatment early with the high specificity that the POC-RDT has exhibited. If paired with an RDT with high sensitivity, this POC-RDT would add a great value to infection management.
Item Open Access Drug Development for Neglected Tropical Diseases: DNDi and the Product Development Partnership (PDP) Model(2016-04-25) Tuttle, JuliaAbstract Neglected tropical diseases (NTDs), including leishmaniasis, Chagas disease, sleeping sickness, dengue fever, and schistosomiasis to name a few, are endemic in 149 countries and impact 1.4 billion people- often the most vulnerable groups in the poorest countries (WHO 2016). Unfortunately, many of these diseases have no vaccines to prevent them, nonexistent or incredibly problematic treatments, and limited resources dedicated to monitoring, controlling, and improving the situation of those who are infected. These diseases may impact millions of people, but the affected population is too poor to exert economic sway and attract investment under the current medical research and development system, and a long-standing market failure has left their needs unmet. However, since the turn of the century, the growing humanitarian concern for NTDs has prompted exploration into innovative partnership and financing mechanisms for developing health technologies for these diseases. Product development partnerships (PDPs), such as the Drugs for Neglected Disease Initiative (DNDi), have emerged to coordinate new collaborations between private industry, academia, and the public sector. Furthermore, the political landscape around NTDs is changing as exemplified by the fact that the World Health Organization (WHO) is endorsing demonstration projects to experiment with "delinkage" principles that aim to separate the innovation market from the price of products and increase affordability and access. These novel approaches to drug development are important case studies in understanding how to best address the market failure around diseases of poverty and offer insight as to what strategies effectively advance the development of innovative health technologies. The lessons learned from the activities of DNDi and other PDPs shed light on how to align the goals of global health with political and economic realities.